Treating three million AIDS patients in sub-Saharan Africa would costmore than $3.3 billion per annum for three years, say Harvard University faculty members. Each patient would cost $1,120 a year to treat, including drugs, testing, monitoring and research, they say, but not including other treatment and prevention programs, which would cost an additional $3 billion a year for only one million people. By the fifth year, total costs of treatment and prevention for three million people would reach around $6.3 billion a year, they add.
Three-four million people in sub-Saharan Africa are in the advanced stages of AIDS, but only about 10,000 have access to antiretroviral drug therapies, says the Harvard report, which adds that clinical trials should be conducted to determine optimum HIV treatment in these countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze